MetaCap

Cingulate (CING) vs PMV Pharmaceuticals (PMVP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed PMV Pharmaceuticals (PMVP) over the past year, gaining 27.8% versus a loss of 33.6%. Cingulate is the larger company by market cap ($67.5 million vs $66.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%PMVP-33.64%
+244%+98%-47%
Nov 21, 20251 yearNov 20, 2026
CING-99.49%PMVP-96.24%
+6%-49%-105%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus PMVP key metrics
MetricCINGPMVP
Share price$4.51$0.876
Market cap$67.48M$66.17M
1-day change-14.26%-33.13%
YTD return+3.92%-29.92%
1-year return+27.76%-33.64%
5-year return—-96.22%
EPS (TTM)$-2.67$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.45M$-77.74M
52-week high$11.89$1.91
52-week low$3.16$0.66
Distance from 52-week high-62.07%-54.14%
Analyst consensusnonestrong_buy
Avg. price target upside+370.07%+356.62%
Average volume178.82K787.50K
Shares outstanding14.96M75.53M
Employees1454
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CING has outperformed PMVP by 61.4 percentage points over the past year.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About PMV Pharmaceuticals

PMVP stock →

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees

CING vs PMVP FAQ

Which is bigger, Cingulate or PMV Pharmaceuticals?

Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $66.17M for PMV Pharmaceuticals (PMVP).

Which stock has performed better over the past year, CING or PMVP?

CING returned +27.76% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and PMV Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons